全文获取类型
收费全文 | 10034篇 |
免费 | 772篇 |
国内免费 | 355篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 176篇 |
妇产科学 | 138篇 |
基础医学 | 861篇 |
口腔科学 | 590篇 |
临床医学 | 931篇 |
内科学 | 1588篇 |
皮肤病学 | 179篇 |
神经病学 | 1260篇 |
特种医学 | 695篇 |
外国民族医学 | 6篇 |
外科学 | 1061篇 |
综合类 | 1628篇 |
现状与发展 | 2篇 |
预防医学 | 347篇 |
眼科学 | 124篇 |
药学 | 447篇 |
5篇 | |
中国医学 | 307篇 |
肿瘤学 | 716篇 |
出版年
2024年 | 10篇 |
2023年 | 177篇 |
2022年 | 240篇 |
2021年 | 422篇 |
2020年 | 392篇 |
2019年 | 334篇 |
2018年 | 307篇 |
2017年 | 338篇 |
2016年 | 327篇 |
2015年 | 340篇 |
2014年 | 603篇 |
2013年 | 543篇 |
2012年 | 515篇 |
2011年 | 496篇 |
2010年 | 444篇 |
2009年 | 494篇 |
2008年 | 510篇 |
2007年 | 560篇 |
2006年 | 479篇 |
2005年 | 402篇 |
2004年 | 321篇 |
2003年 | 290篇 |
2002年 | 303篇 |
2001年 | 256篇 |
2000年 | 212篇 |
1999年 | 179篇 |
1998年 | 163篇 |
1997年 | 180篇 |
1996年 | 121篇 |
1995年 | 128篇 |
1994年 | 121篇 |
1993年 | 101篇 |
1992年 | 100篇 |
1991年 | 73篇 |
1990年 | 71篇 |
1989年 | 58篇 |
1988年 | 62篇 |
1987年 | 52篇 |
1986年 | 66篇 |
1985年 | 92篇 |
1984年 | 51篇 |
1983年 | 29篇 |
1982年 | 39篇 |
1981年 | 40篇 |
1980年 | 31篇 |
1979年 | 14篇 |
1978年 | 14篇 |
1976年 | 12篇 |
1975年 | 14篇 |
1973年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
目的 临床观察白花蛇舌草干预湿热瘀滞型肠内多发息肉患者内镜治疗术后复发情况。方法 采用前瞻性的随机空白对照试验设计,选取2019年9月1日—2020年12月31日上海中医药大学附属普陀医院消化科收治的门诊及住院结直肠多发息肉患者132例作为研究对象。采用随机方法分为对照组和试验组,每组66例。对照组行内镜治疗术给予常规治疗后无药物干预,试验组在对照基础上给予白花蛇舌草汤剂(每日取白花蛇舌草15 g、大枣3枚,煎取400 mL汤剂,分2次饭后温服)治疗,连续干预1年。观察并比较两组术前与术后1年肠道内息肉的复发率、息肉数目、息肉最大直径、中医证候评分及肝肾功能及血常规的差异。结果 干预1年后,试验组复发9例(14.75%),对照组复发21例(33.33%),两组息肉复发率比较,差异有统计学意义(P<0.05)。试验组腺瘤、伴重度异型增生、体质量指数(BMI)≥24 kg·m-2患者治疗后息肉复发率均较对照组同类型降低,差异显著(P<0.05);术后1年试验组息肉最大直径及息肉数目均较对照组显著减小,差异显著(P<0.05);术后1年试验组中医证候各项评分均显著低于对照组(P<0.05);术后1年,两组中医证候疗效比较,差异具有统计学意义(P<0.05),且术前、术后1年两组患者肝肾功能、凝血功能等安全性指标无显著差异。结论 应用白花蛇舌草干预结直肠息肉术后患者,1年后明显降低肠内息肉的复发率,尤以腺瘤性息肉、重度异型增生、BMI超重患者更显著,不仅改善临床症状,还能有效预防结直肠息肉的复发,改善患者的预后。 相似文献
2.
3.
4.
The serrated pathway (SP) can be viewed as two parallel, but partially overlapping, arrays of colorectal precursor lesions, and their respective endpoint carcinomas, that are distinct from those of the conventional adenoma–carcinoma sequence (APC‐pathway). In this review we focus at the outset on the clinical impact, pathological features, molecular genetics and biological behaviours of the various SP cancers. Then we summarize the clinicopathological features, classification and molecular profiles of the two main precursor lesions that anchor the respective pathways: (i) sessile serrated adenoma/polyp (SSA/P), also called sessile serrated lesion (SSL), and (ii) traditional serrated adenoma (TSA). Activating mutations of the RAS–RAF–MAPK pathway initiate and sustain the lesions of the SP, and CpG island methylation of the promoter regions of tumour suppressor and DNA repair genes play the major role in their neoplastic progression. The SP includes microsatellite stable (MSS) carcinomas that are among the most biologically aggressive colorectal carcinomas (CRC), and also accounts for the great preponderance of sporadic hypermutated, mismatch repair (MMR)‐deficient or microsatellite instable (MSI) CRC. The identification, removal and appropriate classification of at‐risk SP precursors and surveillance of individuals who harbour these lesions present a challenge and opportunity for CRC prevention and mortality reduction. 相似文献
5.
Christopher Yeh Cem Atillasoy John T. Seykora Vivian Lee 《Journal of cutaneous pathology》2021,48(1):171-173
Respiratory cysts are benign lesions lined by normal respiratory epithelium. There are few reported cases localized to the orbit, while those of the eyelid are exceedingly rare. Respiratory cysts usually arise either from a non‐hereditary congenital malformation, where they are distinguished as choristomatous, or from trauma. Here, we report a case of a 53‐year‐old man who presented with a large right lower eyelid cyst that was histopathologically diagnosed as a respiratory cyst. 相似文献
6.
7.
8.
Objectives:To reassess the long-term camouflage effects of resin infiltration (Icon, DMG, Hamburg, Germany) of white spot lesions (WSL) and sound adjacent enamel (SAE) achieved in a previous trial. The null hypothesis was tested that there were no significantly different CIE-L*a*b*-ΔE-values between WSL and SAE areas of assessment after at least 24 months (T24) compared to those at baseline (T0).Materials and Methods:Of twenty subjects who received previous resin infiltration treatment of nteeth = 111 nonrestored, noncavitated postorthodontic WSL after multibracket treatment during a randomized controlled trial and were contacted 20 months after baseline, eight subjects (trial teeth nteeth = 40; m/f ratio 1/7; age range (mean; SD) 12–17 [15.25; 2.12] years); response rate: 40%) were available for follow-up after at least 24 months (T24). CIE-L*a*b* differences between summarized color and lightness values (ΔEWSL/SAE) of WSL and SAE were assessed using a spectrophotometer and compared to baseline data assessed prior to infiltration (T0), and those after 6 (T6), and 12 (T12) months using paired t tests at a significance level of α = 5%.Results:T24 assessments were performed after a mean 33.86 (SD: 8.64; Min: 24; Max: 45) months following T0. Mean (SD) ΔEWSL/SAE units of available teeth were 8.76 (5.33) at baseline; 5.5 (2.75) at T6; 5.2 (2.41) at T12; and 5.57 (2.6) at T24. Comparisons of T6, T12, and T24 with T0 yielded highly significant differences, whereas T6–T24 and T12–T24 differences were found to be not significant.Conclusions:Assimilation of infiltrated WSL to the color of adjacent enamel by resin infiltration is considered to be suitable for the long-term improvement in the esthetic appearance of postorthodontic WSL. 相似文献
9.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
10.